Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PLRX

PLRX - Pliant Therapeutics Inc Stock Price, Fair Value and News

$1.25-0.02 (-1.57%)
Market Closed

75/100

PLRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

75/100

PLRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.95

Target 3M

$1.46

Target 6M

$1.64

PLRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PLRX Price Action

Last 7 days

-0.8%

Last 30 days

1.6%

Last 90 days

-23.8%

Trailing 12 Months

-88.5%

PLRX RSI Chart

PLRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PLRX Valuation

Market Cap

76.8M

Price/Earnings (Trailing)

-0.44

Price/Sales (Trailing)

59.12

Price/Free Cashflow

-0.48

PLRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.95

Target 3M

$1.46

Target 6M

$1.64

PLRX Fundamentals

PLRX Revenue

Revenue (TTM)

1.6M

PLRX Earnings

Earnings (TTM)

-175.5M

Earnings Growth (Yr)

54.47%

Earnings Growth (Qtr)

39.26%

PLRX Profitability

Return on Equity

-87.62%

Return on Assets

-63.45%

Free Cashflow Yield

-206.73%

PLRX Investor Care

Shares Dilution (1Y)

0.98%

Diluted EPS (TTM)

-2.87

PLRX Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20239.8M5.0M3.5M1.6M
20226.6M9.8M9.7M9.7M
202115.1M13.2M10.0M7.6M
202053.2M49.4M45.6M41.8M
201900057.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Pliant Therapeutics Inc

PLRX
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
 CEO
 WEBSITEhttps://pliantrx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES155

Pliant Therapeutics Inc Frequently Asked Questions

PLRX is the stock ticker symbol of Pliant Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Pliant Therapeutics Inc is 76.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PLRX's fair value in chart for subscribers.

The fair value guage provides a quick view whether PLRX is over valued or under valued. Whether Pliant Therapeutics Inc is cheap or expensive depends on the assumptions which impact Pliant Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PLRX.

As of Wed Jan 28 2026, PLRX's PE ratio (Price to Earnings) is -0.44 and Price to Sales (PS) ratio is 59.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PLRX PE ratio will change depending on the future growth rate expectations of investors.